#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	15666	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2183	713.9	0	.	n	.	0	A69G	SNP	69	69	A	485	485	G	886	G,A	782,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	15666	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2183	713.9	0	.	n	.	0	C1450T	SNP	1450	1450	C	1866	1866	T	937	T,C	828,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	15666	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2183	713.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1600	1600	C	902	C,T	812,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28294	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3454	816.4	0	.	n	.	0	T695C	SNP	695	695	T	1020	1020	C	942	C	842	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28294	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3454	816.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2296	2296	C	884	C	793	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28294	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3454	816.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2370	2370	A	905	A	824	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28294	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3454	816.4	1	SNP	n	C2597T	0	.	.	2597	2597	C	2922	2922	C	863	C	797	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
blaTEM.WHO_M_pConjugative_00003	blaTEM.WHO_M_pConjugative_00003	1	0	16	20	blaTEM	861	431	100.0	blaTEM.l15.c4.ctg.1	519	2.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Betalactam resistance
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	1952	folP	855	855	100.0	folP.l15.c4.ctg.1	1460	133.2	1	SNP	p	R229S	1	.	.	685	687	AGC	993	995	AGC	217;215;212	A,C;G;C	196,1;194;190	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5366	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3275	163.2	1	SNP	p	S91F	1	.	.	271	273	TTC	509	511	TTC	176;176;183	T;T;C,A	162;157;164,1	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5366	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3275	163.2	1	SNP	p	D95G	1	.	.	283	285	GGC	521	523	GGC	186;184;185	G;G;C	171;168;172	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5366	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3275	163.2	1	SNP	p	G95N	0	.	.	283	285	GGC	521	523	GGC	186;184;185	G;G;C	171;168;172	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	539	1642	mtrR	633	633	99.84	mtrR.l15.c17.ctg.1	1332	122.9	0	.	p	.	0	D79N	NONSYN	235	237	GAT	507	509	AAT	199;204;208	A,G;A;T	185,1;188;187	.	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	539	1642	mtrR	633	633	99.84	mtrR.l15.c17.ctg.1	1332	122.9	1	SNP	p	G45D	0	.	.	133	135	GGC	405	407	GGC	216;211;211	G;G;C	200;194;195	mtrR.WHO_F_01564:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	892	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	1101	80.9	0	.	n	.	0	A197.	DEL	197	197	A	619	619	A	235	A	208	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5052	parC	2304	2304	99.87	parC.l6.c4.ctg.1	2877	174.8	0	.	p	.	0	E91G	NONSYN	271	273	GAG	552	554	GGG	228;223;224	G;G,T;G	209;206,1;209	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5052	parC	2304	2304	99.87	parC.l6.c4.ctg.1	2877	174.8	1	SNP	p	D86N	0	.	.	256	258	GAC	537	539	GAC	228;227;228	G;A;C	208;207;209	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5052	parC	2304	2304	99.87	parC.l6.c4.ctg.1	2877	174.8	1	SNP	p	S87R	0	.	.	259	261	AGT	540	542	AGT	228;229;229	A;G;T	208;210;209	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5052	parC	2304	2304	99.87	parC.l6.c4.ctg.1	2877	174.8	1	SNP	p	S87I	0	.	.	259	261	AGT	540	542	AGT	228;229;229	A;G;T	208;210;209	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5052	parC	2304	2304	99.87	parC.l6.c4.ctg.1	2877	174.8	1	SNP	p	S87W	0	.	.	259	261	AGT	540	542	AGT	228;229;229	A;G;T	208;210;209	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5052	parC	2304	2304	99.87	parC.l6.c4.ctg.1	2877	174.8	1	SNP	p	S88P	0	.	.	262	264	TCC	543	545	TCC	231;232;234	T;C;C	211;210;211	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4484	parE	1986	1986	99.85	parE.l15.c4.ctg.1	2680	166.9	0	.	p	.	0	R427H	NONSYN	1279	1281	CGC	1575	1577	CAC	191;192;194	C;A,G;C	165;165,1;165	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4484	parE	1986	1986	99.85	parE.l15.c4.ctg.1	2680	166.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1524	1526	GGC	190;184;183	G;G;C	174;169;168	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.44.001	penA.44.001	1	1	539	4302	penA	1749	1749	99.94	penA.l15.c17.ctg.1	2245	190.4	0	.	p	.	0	L552P	NONSYN	1654	1656	CTG	1962	1964	CCG	148;149;148	C,G;C;G	115,5;113;116	.	.
penA.44.001	penA.44.001	1	1	539	4302	penA	1749	1749	99.94	penA.l15.c17.ctg.1	2245	190.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1239	1241	GCA	248;251;251	G;C;A,T	223;225;224,1	penA.44.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	539	4302	penA	1749	1749	99.94	penA.l15.c17.ctg.1	2245	190.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1242	1244	ATC	252;251;251	A;T;C	224;222;223	penA.44.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	539	4302	penA	1749	1749	99.94	penA.l15.c17.ctg.1	2245	190.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1254	1256	GTG	242;241;244	G;T;G	213;214;215	penA.44.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	539	4302	penA	1749	1749	99.94	penA.l15.c17.ctg.1	2245	190.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1254	1256	GTG	242;241;244	G;T;G	213;214;215	penA.44.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	539	4302	penA	1749	1749	99.94	penA.l15.c17.ctg.1	2245	190.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1758	1760	ACC	226;227;227	A;C;C,T	205;209;210,1	penA.44.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	539	4302	penA	1749	1749	99.94	penA.l15.c17.ctg.1	2245	190.4	1	SNP	p	T502P	0	.	.	1504	1506	ACG	1812	1814	ACG	231;230;233	A;C,A;G	187;186,1;192	penA.44.001:1:1:T502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	539	4302	penA	1749	1749	99.94	penA.l15.c17.ctg.1	2245	190.4	1	SNP	p	T502V	0	.	.	1504	1506	ACG	1812	1814	ACG	231;230;233	A;C,A;G	187;186,1;192	penA.44.001:1:1:T502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	539	4302	penA	1749	1749	99.94	penA.l15.c17.ctg.1	2245	190.4	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1935	1937	GGC	182;184;182	G;G;C	162;164;158	penA.44.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	539	4302	penA	1749	1749	99.94	penA.l15.c17.ctg.1	2245	190.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1944	1946	GGC	172;171;168	G;G;C	149;150;146	penA.44.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6110	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3108	196.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1620	1622	CCG	238;239;241	C;C;G	200;205;206	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2138	porA	1146	1146	99.65	porA.l6.c4.ctg.1	1684	126.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	515	515	C	154	C	137	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3150	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1517	206.0	0	.	p	.	0	T26A	NONSYN	76	78	ACC	405	407	GCC	263;261;266	G;C;C	235;235;239	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3150	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1517	206.0	0	.	p	.	0	N38E	NONSYN	112	114	AAT	441	443	GAA	261;260;259	G;A;A	234;237;237	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3150	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1517	206.0	0	.	p	.	0	N124S	NONSYN	370	372	AAT	699	701	AGT	271;266;264	A;G,A;T	248;242,1;243	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3150	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1517	206.0	0	.	p	.	0	N134D	NONSYN	400	402	AAT	729	731	GAT	283;283;287	G,A;A;T,G	245,1;247;248,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3150	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1517	206.0	0	.	p	.	0	P175S	NONSYN	523	525	CCA	852	854	TCA	244;242;239	T,A;C;A	226,1;226;223	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3150	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1517	206.0	0	.	p	.	0	A218V	NONSYN	652	654	GCC	981	983	GTC	240;239;236	G;T;C	213;215;216	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3150	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1517	206.0	0	.	p	.	0	F222S	NONSYN	664	666	TTT	993	995	TCT	231;229;228	T;C;T	214;216;215	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3150	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1517	206.0	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1311	1313	GCA	263;266;265	G;C;A	240;242;243	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3150	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1517	206.0	1	SNP	p	G120K	1	.	.	358	360	AAG	687	689	AAG	274;273;273	A,G;A,G;G,T,A	249,1;249,1;247,2,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3150	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1517	206.0	1	SNP	p	A121D	1	.	.	361	363	GAC	690	692	GAC	273;273;274	G,A;A,C;C	249,1;248,1;250	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3150	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1517	206.0	1	SNP	p	D121N	0	.	.	361	363	GAC	690	692	GAC	273;273;274	G,A;A,C;C	249,1;248,1;250	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	12154	rpoB	4179	4179	100.0	rpoB.l6.c30.ctg.1	4958	244.7	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2079	2081	CAT	246;249;247	C;A;T	232;233;230	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1298	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1039	124.2	1	SNP	p	V57M	1	.	.	169	171	ATG	511	513	ATG	299;298;297	A;T;G,A	276;274;271,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
